Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET

Company Participants

Lindsey Allen - Head of Investor Relations and Communications
Justin Klee - Co-Chief Executive Officer
Camille Bedrosian - Chief Medical Officer
James Frates - Chief Financial Officer
Joshua Cohen - Co-Chief Executive Officer

Conference Call Participants

Charlie Yang - Bank of America Merrill Lynch
Michael DiFiore - Evercore ISI
Graig Suvannavejh - Mizuho Securities USA
Basma Radwan - Leerink Partners
Ananda Ghosh - H.C. Wainwright & Co.
Joel Beatty - Robert W. Baird & Co.

Operator

Good morning. My name is Alan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation there will be an opportunity to ask questions. [Operator Instructions] Please be advised this call is being recorded at the company's request.

I would now like to turn the call over to Lindsey Allen, Head of Investor Relations and Communications. Please proceed.

Lindsey Allen

Good morning, and thank you all for joining us today to discuss our third quarter 2024 financial results. With me on the call today are Josh Cohen and Justin Klee, our Co-CEOs; Dr. Camille Bedrosian, our Chief Medical Officer; and Jim Frates, our Chief Financial Officer.

Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

These statements include, but are not limited to, our expectations with respect to avexitide, AMX0035 and AMX0114, statements regarding regulatory and clinical developments, the impact thereof and the expected timing thereof and statements regarding our cash runway. Actual events and results could differ materially from those expressed or implied by any forward-looking statements. You are cautioned not to place any undue reliance on these forward-looking statements, and Amylyx disclaims any obligation to update such statements unless required by law.

Now I will turn the call over to Justin.

Justin Klee

Good morning, and thank you all for joining us. The last few months have been productive in advancing our late-stage pipeline in the effort to fulfill our mission to bring new potential treatments to communities with high unmet needs in neurodegenerative diseases and endocrine conditions. We continue to progress our lead asset avexitide, a GLP-1 receptor antagonist with both FDA breakthrough therapy and orphan drug designations, in diseases with no approved treatment options.